Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...

News headlines Vertex Pharmaceuticals is experiencing notable growth driven by its expanding pipeline and strong market interest, particularly in gene therapies. Recent clinical data and regulatory ...

Every battery-powered tool you could need to take care of your home and yard is on on sale at Amazon for early Black Friday. By Stan Horaczek Published Nov 20, 2025 12:11 PM EST We may earn revenue ...

Shares of Vertex Pharmaceuticals Inc. rose 6.92% to $463.13 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.30% to 6,849.72 ...

News headlines Vertex Pharmaceuticals (VRTX) is gaining traction among investors, buoyed by promising clinical data and potential regulatory advancements. Recent market sentiment also improved due to ...